article thumbnail

Atlas Venture 2023 Year In Review

LifeSciVC

2023 couldn’t end fast enough for most of us in biopharma; its been a tough year in the capital markets, and the industry is facing it’s fair share of headwinds. We then shift to the venture ecosystem and the broader capital markets, highlighting the parallels with twenty years ago, post the genomics bubble in 2002-2003.

Science 97
article thumbnail

Scientific workflow for hypothesis testing in drug discovery: Part 2 of 3

Drug Target Review

As a business executive at IBM Research in New York, Dr Singh led the go-to-market for IBM Watson Genomics Analytics. In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. He was also Vice President and Head of the Microbiome Division at Eagle Genomics Ltd, in Cambridge.

Drugs 69
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biotech Venture Ecosystem: Quick Health Check

LifeSciVC

Indeed, the public equity markets feeling somewhat buoyant for the first time in ages. With a little over 50 new startups raising capital in 4Q24, we’re back to levels not seen for nearly a decade, at the start of the biotech secular bull market in 2013-2014.

Marketing 113
article thumbnail

Biotech Consolidation: Not Really Happening

LifeSciVC

Several years into the post-bubble bear market, the public biotech sector has only contracted by 4.5% Here are the data from BMO Capital Markets, looking at the changes to the overall public market company counts: Shutdowns were only 2% of the sector: declaring failure and closing up shop just hasn’t happened often.

Marketing 112
article thumbnail

Scientific workflow for hypothesis testing in drug discovery: Part 1

Drug Target Review

As a business executive at IBM Research in New York, Dr Singh led the go-to-market for IBM Watson Genomics Analytics. In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. He was also Vice President and Head of the Microbiome Division at Eagle Genomics Ltd, in Cambridge.

RNA 52
article thumbnail

Zigs & Zags – The Opposite of a Great Idea Can Also be a Great Idea

Perficient: Drug Development

Several books have been written on the concept, and many more refer to it when discussing differentiation and disruption within marketing and product development. It’s common that people view novel and innovative, first-to-market groups as having great ideas. The analogy of the “red ocean” of a saturated market drives home his point.

Marketing 116
article thumbnail

NANOBIOTIX Announces Pricing of Global Offering and Approval to List on NASDAQ Global Select Market

The Pharma Data

The ADSs have been approved for listing on the Nasdaq Global Select Market and are expected to begin trading on December 11, 2020 under the ticker symbol “NBTX.” The Company’s ordinary shares are listed on the regulated market of Euronext Paris under the ticker symbol “NANO.”.